Table 3 Reviews of reported cases of methotrexate-associated T-cell lymphoproliferative disorders
Author (year) | Age/Sex | Subtype | Disease site | MTX duration (year) | First line management | SR | Res | Recurrence or progression | Outcome |
|---|---|---|---|---|---|---|---|---|---|
Hatanaka (2010) | 71/F | AITL | Cervical, axillary, mediastinal, and paraaortic LN | 3 | Off MTX | + | CR | No | AWOD |
Hatanaka (2010) | 68/M | AITL | Supraclavicular, axillary, parabroncheal, and paraaortic LN | 3 | Off MTX | + | CR | No | AWOD |
Hatanaka (2010) | 67/M | AITL | Cervical, supraclavicular, and mediastinal LN | 6 | Off MTX | + | CR | Yes | AWOD |
Hoshida(2007) | 60/M | AITL | LNs | 0.6 | Off MTX | + | CR | Yes | A |
Ishibuchi (2015) | 66/F | AITL | Inguinal LN | 0.4 | Off MTX | + | CR | Yes (DLBCL) | AWOD |
Jamal (2016) | 66/F | CD8+EBV+ TLPD | Oral cavity | 5 | Off MTX | + | CR | No | AWOD |
Nemoto (2010) | 60/M | CD8+EBV+ TLPD | Abdominal cavity, subcutis | NA | Off MTX | + | CR | No | AWOD |
Claudino (2016) | 66/F | CD8+EBV+ TLPD | Skin | NA | Off MTX | + | CR | No | AWOD |
Hatachi (2010) | 75/F | CD8+EBV+ TLPD | NA | NA | Off MTX, acyclovir | + | CR | No | AWOD |
Koji (2014) | 48/F | CD8+ TLPD | Cervical, submandibular, supraclavicular, and paraaortic LN, liver, spleen, kidney | 11 | Off MTX | + | CR | No | AWOD |
Takajo (2018) | 74/F | ATLL | Cervical, mediastinal, and abdominal LN | 5 | Off MTX | + | CR | Yes | DOD |
